US 12,442,018 B2
Recombinant cytomegalovirus vectors as vaccines for tuberculosis
Thomas G. Evans, New York, NY (US); Ravi Anantha, New York, NY (US); Aurelio M. Bonavia, New York, NY (US); Dominick J. Laddy, New York, NY (US); Louis Picker, Beaverton, OR (US); Scott Hansen, Beaverton, OR (US); and Guangwu Xu, Beaverton, OR (US)
Assigned to International AIDS Vaccine Initiative, Inc., New York, NY (US); and Oregon Health and Science University, Portland, OR (US)
Filed by International AIDS Vaccine Inititative, Inc., New York, NY (US); and Oregon Health and Science University, Portland, OR (US)
Filed on Oct. 27, 2023, as Appl. No. 18/496,076.
Application 18/496,076 is a continuation of application No. 17/365,509, filed on Jul. 1, 2021, granted, now 11,834,669.
Application 17/365,509 is a continuation of application No. 15/628,921, filed on Jun. 21, 2017, granted, now 11,091,775, issued on Aug. 17, 2021.
Claims priority of provisional application 62/478,099, filed on Mar. 29, 2017.
Claims priority of provisional application 62/353,432, filed on Jun. 22, 2016.
Prior Publication US 2024/0150789 A1, May 9, 2024
Int. Cl. C12N 15/86 (2006.01); A61K 39/00 (2006.01); A61K 39/04 (2006.01); C07K 14/35 (2006.01)
CPC C12N 15/86 (2013.01) [A61K 39/04 (2013.01); C07K 14/35 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/53 (2013.01); C07K 2319/00 (2013.01); C12N 2710/16143 (2013.01); C12N 2710/16151 (2013.01); C12N 2710/16171 (2013.01); C12N 2800/204 (2013.01); C12N 2800/30 (2013.01)] 15 Claims
 
1. A method of preparing a rhesus cytomegalovirus (RhCMV) or a human cytomegalovirus (HCMV) vaccine vector comprising a nucleic acid sequence encoding an expressible Mycobacterium tuberculosis (Mtb) antigen, the method comprising:
i) inserting into a RhCMV genome or a HCMV genome a nucleic acid sequence encoding an expressible Mtb antigen consisting of Ag85A-Ag85B-Rv3407, Rv1733-Rv2626c, and Ag85A-ESAT6-Rv3407-Rv2626c-RpfA-RpfD; and
ii) attenuating the RhCMV genome or the HCMV genome.